Compare US Global Jets ETF (JETS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? US Global Jets ETF trades at $26 (market cap $766.85M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 6.5× US Global Jets ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 27 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| JETS | TVTX | |
|---|---|---|
Market Cap | $766.85M | $5.02B |
Volume | 3,093,704 | 2,060,842 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $67.52 |
52-Week Low | $23.64 | $26.79 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS is trading at $26.80, down 0.81% with a bearish technical outlook indicated by moving averages. The ETF faces headwinds from rising fuel costs and geopolitical tensions, though strong travel demand provides some support. Recent news highlights underperformance compared to aerospace/defense ETFs, with fuel expenses surging 85% in May 2026 according to Reuters.
The outlook remains cautious due to fuel price volatility and competitive pressure from alternative aviation ETFs. Near-term performance depends on fuel cost management and travel demand sustainability, with technical support at $26 providing a key level to watch.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
